Vanguard Global Advisers
EBS icon

Vanguard Global Advisers’s Emergent Biosolutions EBS Stock Holding History

Vanguard Global Advisers’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Sell
48,674
-105,495
-68% -$883K ﹤0.01% 2191
2026
Q1 		$1.28M Buy
+154,169
New +$1.6M ﹤0.01% 1487

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Vanguard Global Advisers's EBS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Emergent Biosolutions (EBS) stake by 68% in Q2 2026, selling an estimated $883K and leaving 48,674 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

Vanguard Global Advisers first reported a position in EBS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.28M in Q1 2026. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Vanguard Global Advisers held 48,674 shares of Emergent Biosolutions worth $408K as of Q2 2026.
  • Vanguard Global Advisers sold 105,495 Emergent Biosolutions shares in Q2 2026, an estimated $883K.
  • Emergent Biosolutions made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2191 holding.
  • Vanguard Global Advisers first reported a position in Emergent Biosolutions in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Emergent Biosolutions position peaked at $1.28M in Q1 2026.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.